Coronavirus company news summary - Abingdon introduces BioSURE antibody self-test - QIAGEN receives contract to boost reagents and kits for molecular tests - Verdict Medical Devices
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – Abingdon introduces BioSURE antibody self-test – QIAGEN receives contract to boost reagents and kits for molecular tests

24 Aug 2021

Abingdon Health has launched the CE marked BioSURE COVID-19 IgG Antibody Self Test, which requires a small drop of finger-prick blood and delivers results within 20 minutes. The test can be used to check and track antibody status before and after vaccination and after Covid-19 infection. Abingdon entered an exclusive manufacturing agreement with BioSure for the test in July this year. BioSure is the legal manufacturer while Abingdon will be the exclusive global producer of the test.

QIAGEN Beverly has received a $0.6m contract from the US Department of Defense (DoD) to boost the production capacity of enzymatic reagents and reagent kits required for Covid-19 molecular diagnostic tests. The reagents manufactured by the company are used to identify SARS-CoV-2 in samples. This expansion will enable the company to grow its per month production of reagent kits by 7,000 and enzymes by 5,100mg at its Beverly, Massachusetts, plant by the end of February next year to support domestic laboratory Covid-19 testing.

Contact tracing startup Traceperts has begun crowdfunding at Indiegogo to support their ‘Super Antigen Test’ Mega Covid Complete, which tests, contact traces and reports to local health authorities. The test leverages the company’s SkyCovid Self Reporting Database Technology. A Covid-19-positive individual can fill out the relevant information on the reporting website. The information, which is sent via the SkyCovid Database Technology, facilitates the local health authority to swiftly plan, mitigate and add to their Covid positive tallies.